Skip to Content

Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia

The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil (Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile dysfunction. Tadalafil is approved for use under another brand name (Adcirca) for treatment of pulmonary arterial hypertension. The other PDE-5 inhibitors available in the US for treatment of erectile dysfunction (sildenafil [Viagra]; vardenafil [Levitra]) have also been reported to be effective for treatment of BPH signs and symptoms, but have not been approved for this indication by the FDA....
Cannot Access - We are sorry, but you cannot access the requested article.
login now
login now
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1377
Article Code: 1377b
Date: November 14, 2011
Volume: 53
Pages: 89-90

 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.